Navigation Links
ChemDiv and Avineuro Extend Collaboration on Alzheimer's Disease and Schizophrenia
Date:11/21/2008

SAN DIEGO, Nov. 21 /PRNewswire/ -- ChemDiv Inc. and Avineuro Pharmaceuticals Inc. have extended the term of their research and development collaboration including formulation, safety and early clinical development studies in areas of neurodegenerative and psychiatric disorders. R&D services will be provided by Chemical Diversity Research Institute, ChemDiv's research subsidiary based in Moscow. The new agreement provides for research funding of clinical candidate compounds to POC. Avineuro is responsible for further clinical development and commercialization of drug candidates AVN101, AVN211, and additional compounds that may be nominated for development from the ongoing research and discovery under the agreement. In September, ChemDiv entered into an out-licensing and collaboration agreement with Avineuro to develop multiple compounds for Alzheimer Disease and schizophrenia. Under the agreement, Avineuro obtained exclusive worldwide rights to clinical development candidates AVN101, AVN211, and lead compounds in various stages of pre-clinical development. ChemDiv will provide pre-clinical development services to nominate additional backup leads and candidates for Avineuro.

About Avineuro Pharmaceuticals, Inc.:

Avineuro Pharmaceuticals, Inc. discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Founded in August 2008 and headquartered in San Diego, California, Avineuro is managed by seasoned professionals experienced in drug discovery and development. By acquiring lead compounds through collaborations and partnerships, Avineuro plans to develop novel products and extend the reach of marketed compounds for indications with a significant commercial potential. Avineuro emphasizes a rational approach that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

About ChemDiv, Inc.

ChemDiv, Inc. is a global chemistry-driven contract research organization accelerating discovery and development of novel therapies through comprehensive Discovery outSource(TM) services, including pre-clinical development, discovery biology, medicinal and synthetic chemistry.


'/>"/>
SOURCE ChemDiv, Inc.; Avineuro Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChemDiv and Achaogen Enter Into a Discovery Collaboration
2. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
3. Roche Extends Tender Offer for Ventana
4. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
5. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
6. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
7. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
8. ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook
9. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
10. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Disappearing forests ... the lives of over 5.5 million people each year. Especially those living in larger ... startup Treepex - based in one of the most pollution-affected countries globally - decided ...
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent ... entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 ... joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces a ... in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” ...
Breaking Biology Technology:
(Date:7/20/2017)... (NYSE: DAL ) customers now can use fingerprints instead of ... Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May ... boarding process to allow eligible Delta SkyMiles Members who are enrolled in ...
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
Breaking Biology News(10 mins):